Doximity DOCS: Guidance Raise and AI Search Drive 32.6% Surge

Doximity shares jumped 32.6% after the health technology company reported a Q1 FY2027 revenue beat and raised its full-year guidance, with AI Search query volume rising 25% quarter-over-quarter and the company's clinical AI tools reshaping its revenue profile.

Lead

What Happened

Doximity reported Q1 FY2027 revenue of $156.6 million, compared with $145.9 million in the same period one year earlier, and significantly ahead of the company's guidance range of $151–$152 million. Adjusted EBITDA reached $75 million, representing a 48% margin and exceeding the top of guidance by 8%.

The company simultaneously raised full-year FY2027 revenue guidance to a range of $671 million to $681 million, up from the prior range of $664 million to $676 million. The Doximity guidance raise was accompanied by a full-year adjusted EBITDA range of $309 million to $329 million, representing a 47% margin at the midpoint. For Q2 FY2027, Doximity guided revenue of $170 million to $171 million with adjusted EBITDA of $80.5 million to $81.5 million.

Net income for the quarter came in at $24.3 million ($0.13 per diluted share), below the year-ago figure of $53.3 million ($0.27 per share), as the company deliberately accelerated investment in its AI infrastructure and clinical tools.

AI Search: The Defining Driver

At the center of the investment thesis is Doximity's AI Search product — a clinical query tool embedded within its physician platform. AI Search query volume rose 25% quarter-over-quarter, a metric management cited as evidence of deepening physician engagement. Quarterly active workflow prescribers grew more than 30% year-over-year to record highs, with nearly half of that cohort deploying AI-powered tools during the quarter.

CEO Jeff Tangney disclosed that Doximity's AI search product generates revenue more than ten times its per-search operating cost, a unit-economics profile that management said opens access to pharmaceutical "AI innovation budgets" and "insights and analytics" spend categories that the company had not previously captured.

Doximity also reported 165 signed health tech AI clients across health systems, an indication that hospital-side commercial adoption is outpacing earlier expectations. The company's clinical AI assistant, Doximity Ask, was recognized as the top-performing U.S.-based model in the NOHARM benchmark, an independent evaluation of clinical accuracy, with a clinical error rate of 4.8% — the lowest among domestic AI systems tested.

Market Reaction

DOCS surged more than 70% in after-hours trading on the night of the earnings release before paring gains as the regular session opened Friday. The +32.6% gain registered by session's end reflected a partial pullback from that initial spike but still represented one of the largest single-session moves in the company's listed history. Short-covering contributed to the amplified initial move, as bearish positions were forced to unwind against the improving fundamental data.

Strategic Context

Doximity, which operates a professional network connecting more than 80% of U.S. physicians, has positioned its AI layer as the mechanism for monetizing that engagement more deeply. The company's traditional revenue model — pharmaceutical marketing spend directed at physician audiences — is being augmented by AI workflow subscriptions and clinical intelligence licensing.

The guidance raise signals management's confidence that a more stable pharmaceutical advertising environment, combined with the AI commercial pipeline, is durable rather than episodic. The compression in net income is a deliberate tradeoff: the company has chosen to invest aggressively in AI capacity during a period when its unit economics are validating the bet.

Outlook

Doximity's updated FY2027 guidance and the commercial traction of AI Search suggest the company has successfully moved from proof-of-concept to monetization. With query volume scaling, health system client wins accelerating, and cost-per-search economics increasingly favorable, the margin compression of the current fiscal year is framed as investment rather than structural deterioration. Whether the platform can sustain prescriber engagement growth and expand into adjacent clinical AI budgets will determine whether the current guidance trajectory proves conservative or aspirational.